Insect sting allergy and venom immunotherapy

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 2 SUPPL. 1, 2006, Pages

  Golden, David B K ^a  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INSECT VENOM;

CONFERENCE PAPER; DIAGNOSTIC TEST; DRUG SAFETY; DRUG WITHDRAWAL; FATALITY; HONEYBEE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSECT ALLERGY; LOCAL SKIN REACTION; MAINTENANCE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOALLERGOSORBENT TEST; SKIN TEST; SYSTEMIC DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33344475110     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60897-6     Document Type: Conference Paper

References (46)

1. Oude-Elberink JNG, deMonchy JGR, vanderHeide S, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in yellow jacket allergic patients. J Allergy Clin Immunol. 2002;110:174-182.
2. Golden DBK, Kagey-Sobotka A, Hamilton RG, Norman PS, Lichtenstein LM. Insect allergy with negative venom skin tests. J Allergy Clin Immunol. 2001;107:897-901.
3. Day J. A comparison of venom concentrations of 0.1 μg/ml and 1.0 μg/ml as indicator of sensitivity to honeybee stings. J Allergy Clin Immunol. 1986;77:142.
4. Golden DBK, Langlois J, Valentine MD. Treatment failures with whole body extract therapy of insect sting allergy. JAMA. 1981;246:2460-2463.
5. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299:157-161.
6. Reisman RE. Natural history of insect sting allergy: Relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol. 1992;90:335-339.
7. Franken HH, Dubois AEJ, Minkema HJ, vanderHeide S, deMonchy JGR. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol. 1994;93:431-436.
8. vanderLinden PG, Hack CE, Struyvenberg A, vanderZwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol. 1994;94:151-159.
9. Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol. 1984;74:494-498.
10. Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A Prospective study of the natural history of large local reactions following Hymenoptera stings in children. J Pediatr. 1984;104:664-668.
11. Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med. 1990;323:1601-1603.
12. Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children with and without venom immunotherapy. N Engl J Med. 2004;351:668-674.
13. Muller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity: bee venom versus wholebody extract. Allergy. 1979;34:369-378.
14. Walker R, Jacobs J, Tankersly M, Hagan L, Freeman T. Rush immunotherapy for the prevention of large local reactions secondary to imported fire ant stings. J Allergy Clin Immunol. 1999;103:S180.
15. Golden DBK, Hamilton RG, Kelly D, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Venom immunotherapy for large local reactions to insect stings: a pilot study [abstract]. J Allergy Clin Immunol. 2004;113:874.
16. Golden DBK, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med. 1980;92:620-624.
17. Bernstein JA, Kagan SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy. 1994;73:423-428.
18. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy. 1993;23:226-230.
19. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy. 2003;33:58-64.
20. Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy. 2003;91:405-410.
21. Jacobsen L, Nuchel-Peterson B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts, IV: results from long-term (6 year) follow-up. Allergy. 1997;52:914-920.
22. Eng PA, Reinhold M, Gnehm HPE. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2001;57:306-312.
23. Cools M, vanBever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy. 2000;55:69-73.
24. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995;96:879-885.
25. DesRoches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, V: duration of the efficacy of immunotherapy after its cessation. Allergy. 1996;51:430-433.
26. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow up study in patients with grass pollen rhinitis. Allergy. 1988;43:523-529.
27. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med. 1999;341:468-475.
28. Golden DBK, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000;105:385-390.
29. Moffitt JE, Golden DBK, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114:869-886.
30. Goldberg A, Confino-Cohen R, Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol. 2001;107:902-906.
31. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1997;100:458-463.
32. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific allergen immunotherapy. J Allergy Clin Immunol. 2001;107:81-86.
33. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027-1032.
34. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992;89:529-535.
35. Golden DBK, Lawrence ID, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol. 1992;90:386-393.
36. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102:98-106.
37. Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199:1567-1575.
38. Plaut M, Rotrosen D. Tolerance induced by allergen immunotherapy. In: Lockey RF, Bukantz SC, Bousquet J, eds. Allergens and Allergen Immunotherapy. 3rd ed. New York, NY: Marcel Dekker; 2004:681-682.
39. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 1996;97:579-587.
40. Golden DBK, Kwiterovich KA, Addison BA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol. 1998;101:298-305.
41. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol. 1991;88:339-348.
42. Urbanek R, Forster J, Kuhn W. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr. 1985;107:367-371.
43. Haugaard L, Norregaard OFH, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol. 1991;87:699-702.
44. Muller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping venom immunotherapy in 86 patients. J Allergy Clin Immunol. 1991;87:702-709.
45. Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol. 1993;92:831-836.
46. Lerch E, Muller U. Long-term protection after stopping venom immunotherapy. J Allergy Clin Immunol. 1998;101:606-612.